Compositions and methods for treating retinal degradation

Patent metadata

Field	Value
Publication number	US-2016263114-A1
Application number	US-201615142087-A
Country	US
Kind code	A1
Filing date	Apr 29, 2016
Priority date	Aug 1, 2013
Publication date	Sep 15, 2016
Grant date	—

Abstract

The present disclosure relates to compositions and methods for treating retinal damage and/or retinal degradation. More specifically, this disclosure relates to methods for treating degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and/or a nucleoside or nucleotide reverse transcriptase inhibitor.

First claim

What is claimed is:

1 . A method for treating retinal damage, comprising:
administering an effective amount of a composition to a subject in need thereof, wherein the composition comprises a reverse transcriptase inhibitor selected from:
(i) a compound having the structure of

 or a pharmaceutically acceptable salt thereof;
(ii) a compound having the structure of

 or a pharmaceutically acceptable salt thereof;
(iii) stavudine (d4T);
(iv) lamivudine (3TC);
(v) cordycepin;
(vi) azidothymidine (AZT);
(vii) abacavir (ABC); and
(viii) a combination thereof.

2 . The method of claim 1 , comprising inhibiting inflammasome activation by Alu RNA associated with a cell.

3 . The method of claim 2 , wherein the cell is a retinal pigmented epithelium cell, a retinal photoreceptor cell, a choroidal cell, or a combination thereof.

4 . The method of claim 1 , comprising reducing ATP-induced permeability of a cell.

5 . The method of claim 4 , wherein the cell is a retinal pigmented epithelium cell, a retinal photoreceptor cell, a choroidal cell, or a combination thereof.

6 . The method of claim 1 , comprising reducing an amount of mitochondrial reactive oxygen species in a cell.

7 . The method of claim 1 , comprising inhibiting activation of at least one inflammasome in a subject's eye.

8 . The method of claim 7 , wherein the at least one inflammasome is selected from an NLRP3 inflammasome, an IL-1beta inflammasome, and a combination thereof.

9 . The method of claim 1 , wherein the composition comprises a pharmaceutically acceptable carrier.

10 . A compound having the structure

 or a pharmaceutically acceptable salt thereof.

11 . A pharmaceutical composition comprising the compound of claim 10 and a pharmaceutically acceptable carrier.

12 . A compound having the structure

 or a pharmaceutically acceptable salt thereof.

13 . A pharmaceutical composition comprising the compound of claim 12 and a pharmaceutically acceptable carrier.

Assignees

• Univ Kentucky Res Found

Inventors

• Ambati Jayakrishna
• Fowler Benjamin

Classifications

• A61K31/706

  containing six-membered rings with nitrogen as a ring hetero atom · CPC title

• A61K31/506 Primary

  not condensed and containing further heterocyclic rings · CPC title

• A61K31/7068

  having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid · CPC title

• C07D411/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• A61K31/7064

  containing condensed or non-condensed pyrimidines · CPC title